Do you want to read an article? Please log in or register.
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial
Blindness and Vision Impairment
RECOMMENDED
Related content
Retinal Diseases
Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial
JAMA Ophthalmol.
Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, Reichel FFL, Kuehlewein L, Kahle NA, Peters T, Girach A, Zrenner E, Ueffing M, MacLaren RE, Bartz-Schmidt KU, Wilhelm B
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal Diseases
Technique of retinal gene therapy: delivery of viral vector into the subretinal space
Eye (Lond).
Xue K, Groppe M, Salvetti AP, MacLaren RE
doi: 10.1038/eye.2017.158.
COMMENTED
Retinal Diseases
The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
J Clin Med
Lee JY, Kim MH, Jeon SH, Lee SH, Roh YJ
doi: 10.3390/jcm10194295
Retinal Diseases
The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients
Ophthalmology.
Ashtari M, Nikonova ES, Marshall KA, Young GJ, Aravand P, Pan W, Ying GS, Willett AE, Mahmoudian M, Maguire AM, Bennett J
doi: 10.1016/j.ophtha.2017.01.029.
Retinal Diseases
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial
Ophthalmology.
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF
doi: 10.1016/j.ophtha.
COMMENTED
Ocular Oncology
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5132.
Further Publications
Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial
Am J Ophthalmol
van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF
doi: 10.1016/j.ajo.2021.06.020
Blindness and Vision Impairment
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial
JAMA Ophthalmol.
Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG
doi: 10.1001/jamaophthalmol.
Retinal Diseases
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Lancet.
Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N
doi: 10.1016/S0140-6736(19)31344-3.